Zorzela, Liliane
Khamba, Baljit
Sparks, Emma
Necyk, Candace
Urichuk, Liana
Katzman, Martin A.
Koczerginski, David
Chue, Pierre
Barnes, Joanne
Vohra, Sunita http://orcid.org/0000-0002-6210-7933
Funding for this research was provided by:
Canadian Institute for Health Research (RES0021177)
Alberta Innovates - Health Solutions (RES0025318)
Article History
Accepted: 28 June 2021
First Online: 28 July 2021
Declarations
:
: This study received financial support from two Grants agencies in a partnership fund, Canadian Institute for Health Research (CIHR) (RES0021177) and Alberta Innovates Health Solutions (RES0025318), both from Edmonton, Alberta, Canada. The Grant agencies had no interventions or participation in the study or manuscript development.
: Martin Katzman is a member on the advisory board for the following drug companies: Abbvie, Eisai, Empower Pharma, Janssen, Otsuka, Pfizer, Purdue, Santé Cannabis, Shire, Takeda and Tilray. He has also received honoraria from Allergan, Jansen, Lundback, Otsuka, Pfizer, Purdue, Shire, Takeda and Tilray, a research grant from Pfizer, and is involved in a clinical trial with Lundbeck. Joanne Barnes reports non‐financial support from Achieve Life Sciences during a clinical trial of cytisine. She also reports personal fees from New Zealand Ministry of Health Natural Health Products (NHPs) Regulations Subcommittee on the Permitted Substances List (member of subcommittee 2016–17), non‐financial support from Uppsala Monitoring Centre, Sweden (who manages the technical and scientific aspects of the WHO Programme for International Drug Monitoring); honorary consultant and herbal safety signal reviewer (2004–current), outside the submitted work. These conflicts are not related to this paper. All other authors have no conflicts of interest to disclose.
: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
: As is consistent with other SONAR studies, the initial screening questions are a part of ideal clinical care (e.g., best possible medication history), so HREB approval was granted making additional research consent unnecessary.
: This study was approved by the Human Research Ethics Board at the University of Alberta (MS21 Pro00025387). The STROBE guideline was used to report this study.
: Not applicable.
: Contribution statement: LZ, BK, CN, ES collect the study data and helped on the development of the manuscript, LU, PC, DK, MK, JB and SV developed the study methods and helped drafting the manuscript. All authors read and approved the final version.